Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
复制标题
作者：
Therapy for multiple myeloma (MM) has dramatically changed in the past decade with introduction of new drugs, but it is not clear if the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two five-year periods by diagnosis, 2001–2005 and 2006–2010. The median estimated follow up for the cohort was 5.9 years with 47% alive at last follow up. The median overall survival (OS) for the entire cohort was 5.2 years; 4.6 years for patients in the 2001–2005 group compared with 6.1 years for the 2006–2010 cohort (P=0.002). The improvement was primarily seen among patients over 65 years; the 6-year OS improving from 31% to 56%; P<0.001. Only 10% of patients died during the first year in the latter group, compared with 17% in the earlier cohort (P<0.01), suggesting improvement in early mortality. The improved outcomes were linked closely to use of one or more new agents in initial therapy. The current results confirm continued survival improvement in MM and highlight the impact of initial therapy with novel agents. Most importantly, we demonstrate that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably.
登录
查看更多内容
影响因子：
39.2
作者：
DIMOPOULOS, MA;BARLOGIE, B;ALEXANIAN, R
通讯作者：
ALEXANIAN, R
影响因子：
45.3
作者：
Decaux, Olivier;Lode, Laurence;Minvielle, Stephane
通讯作者：
Minvielle, Stephane
影响因子：
11.4
作者：
Kuiper, R.;Broyl, A.;Sonneveld, P.
通讯作者：
Sonneveld, P.
影响因子：
1.9
作者：
Kyle, Robert A.
通讯作者：
Kyle, Robert A.
DOI：
10.1200/jco.2011.37.8919
发表时间：
2012-02-01
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Anderson KC
通讯作者：
Anderson KC